This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 23, 2024
•
9 min read
Agilent buys CDMO Biovectra, Samsung Bioepis's Soliris biosimilar lands FDA approval, Innovent Biologics China Ph3 type 2 diabetes win, CSL Vifor looks to make antitrust amends, and bluebird bio hits fertility program coverage issues
Jul 22, 2024
6 min read
Eli Lilly ok'd to sell Zepbound in China, a $520M animal health antibody acquisition, Siga lands $113M US smallpox antiviral supply contract, GRO Biosciences GROws with $60.3M Series B, Artiva bests their own expectations with $167M IPO, and ICER isn't happy at all with Pfizer's ATTR heart disease med price
Jul 19, 2024
Novartis has a good (also not good) earnings day, Exscientia buys back asset from partner GT Apeiron, a 7th person seemingly cured of HIV infection, argenx showcases 2030 plans, J&J discontinues Addex Therapeutics epilepsy partnership
Jul 18, 2024
8 min read
Roche's obesity pill posts positive Ph1, J&J earnings stay positive despite looming IRA, NGM nabs $122M raise after going private, Sanofi doubles Hyderabad workforce, Actuate's $50M upcoming IPO, FDA launches rare disease innovation hub, and Roche's Genentech bails on Relay Therapeutics partnership
Jul 17, 2024
Cardurion raises $260M for cardiac small molecules, CordenPharma invests nearly a billion in GLP-1 capacity expansion, Sionna gets hands on abandoned AbbVie CF asset, Vertex and Orum partner on new Casgevy conditioning regiment, ICER doesn't like Verona's COPD treatment price
Jul 16, 2024
Legend Biotech's alleged takeover bid, Artiva (2nd attempt) IPO aims for $135M raise, Vertex wants to cover Casgevy patient's fertility support services, Lexeo's gene therapy data disappoints, and GSK moves into London HQ
Jul 15, 2024
AbbVie's Rinvoq label expansion application, semaglutide correlates with lowered dementia risks, IDEAYA Biosciences raises over $300M through public offering, two health SPACS launch with a combined $400M, Spark Therapeutics layoffs, and Big Pharma & PBMs play drug price blame game
Jul 12, 2024
7 min read
Pfizer's one-daily obesity pill moves forward, Illumina competitor lands $277M Series D, Novo Nordisk once-weekly insulin injection rejected by FDA, Novartis to shutter San Diego R&D site, and FTC sues Pharmacy Benefit Managers over insulin prices
Jul 11, 2024
Flagship raises a colossal $3.5B 8th round, Illumina buys Fluent Biosciences, Pfizer and Evoteic sign drug discovery pact, Amylyx buys a Ph3 ready GLP-1 asset, and Allucent tapped for BARDA decentralized clinical trial initiative
Jul 10, 2024
FTC comes out swinging against PBMs, uniQure stock jumps on Huntington's data, new anti-inflammatory player raises $70M, J&J sweeps aside two lawsuits, and Interius BioTherapeutics ok'd for first in-human in-vivo CAR-T trial
Jul 9, 2024
Eli Lilly buys Morphic for $3.2B, Roche gets FDA approval for Vabysmo prefilled syringe, SmartCella raises €50M (half from Novartis), and Eli Lilly bests Novo Nordisk in weight-loss head-to-head, Grifols may go private
Jul 8, 2024
5 min read
Another ADC Biotech bags $100M+ in funding, Lotte Biologics' groundbreaking for multibillion $ project, CSL Behring's Hemophilia B gene therapy has its first two patients, and GLP-1s reduce risk of obesity-linked cancers in diabetics
